Combined Immunotherapy Improves Outcome for Replication-Repair-Deficient (RRD) High-Grade Glioma Failing Anti-PD-1 Monotherapy : A Report from the International RRD Consortium
©2023 American Association for Cancer Research..
Immune checkpoint inhibition (ICI) is effective for replication-repair-deficient, high-grade gliomas (RRD-HGG). The clinical/biological impact of immune-directed approaches after failing ICI monotherapy is unknown. We performed an international study on 75 patients treated with anti-PD-1; 20 are progression free (median follow-up, 3.7 years). After second progression/recurrence (n = 55), continuing ICI-based salvage prolonged survival to 11.6 months (n = 38; P < 0.001), particularly for those with extreme mutation burden (P = 0.03). Delayed, sustained responses were observed, associated with changes in mutational spectra and the immune microenvironment. Response to reirradiation was explained by an absence of deleterious postradiation indel signatures (ID8). CTLA4 expression increased over time, and subsequent CTLA4 inhibition resulted in response/stable disease in 75%. RAS-MAPK-pathway inhibition led to the reinvigoration of peripheral immune and radiologic responses. Local (flare) and systemic immune adverse events were frequent (biallelic mismatch-repair deficiency > Lynch syndrome). We provide a mechanistic rationale for the sustained benefit in RRD-HGG from immune-directed/synergistic salvage therapies. Future approaches need to be tailored to patient and tumor biology.
SIGNIFICANCE: Hypermutant RRD-HGG are susceptible to checkpoint inhibitors beyond initial progression, leading to improved survival when reirradiation and synergistic immune/targeted agents are added. This is driven by their unique biological and immune properties, which evolve over time. Future research should focus on combinatorial regimens that increase patient survival while limiting immune toxicity. This article is featured in Selected Articles from This Issue, p. 201.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:14 |
|---|---|
| Enthalten in: |
Cancer discovery - 14(2024), 2 vom: 08. Feb., Seite 258-273 |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 09.02.2024 Date Revised 10.02.2024 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1158/2159-8290.CD-23-0559 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM363168737 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM363168737 | ||
| 003 | DE-627 | ||
| 005 | 20240210232731.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1158/2159-8290.CD-23-0559 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1286.xml |
| 035 | |a (DE-627)NLM363168737 | ||
| 035 | |a (NLM)37823831 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Das, Anirban |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Combined Immunotherapy Improves Outcome for Replication-Repair-Deficient (RRD) High-Grade Glioma Failing Anti-PD-1 Monotherapy |b A Report from the International RRD Consortium |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 09.02.2024 | ||
| 500 | |a Date Revised 10.02.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a ©2023 American Association for Cancer Research. | ||
| 520 | |a Immune checkpoint inhibition (ICI) is effective for replication-repair-deficient, high-grade gliomas (RRD-HGG). The clinical/biological impact of immune-directed approaches after failing ICI monotherapy is unknown. We performed an international study on 75 patients treated with anti-PD-1; 20 are progression free (median follow-up, 3.7 years). After second progression/recurrence (n = 55), continuing ICI-based salvage prolonged survival to 11.6 months (n = 38; P < 0.001), particularly for those with extreme mutation burden (P = 0.03). Delayed, sustained responses were observed, associated with changes in mutational spectra and the immune microenvironment. Response to reirradiation was explained by an absence of deleterious postradiation indel signatures (ID8). CTLA4 expression increased over time, and subsequent CTLA4 inhibition resulted in response/stable disease in 75%. RAS-MAPK-pathway inhibition led to the reinvigoration of peripheral immune and radiologic responses. Local (flare) and systemic immune adverse events were frequent (biallelic mismatch-repair deficiency > Lynch syndrome). We provide a mechanistic rationale for the sustained benefit in RRD-HGG from immune-directed/synergistic salvage therapies. Future approaches need to be tailored to patient and tumor biology | ||
| 520 | |a SIGNIFICANCE: Hypermutant RRD-HGG are susceptible to checkpoint inhibitors beyond initial progression, leading to improved survival when reirradiation and synergistic immune/targeted agents are added. This is driven by their unique biological and immune properties, which evolve over time. Future research should focus on combinatorial regimens that increase patient survival while limiting immune toxicity. This article is featured in Selected Articles from This Issue, p. 201 | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a CTLA-4 Antigen |2 NLM | |
| 650 | 7 | |a Antineoplastic Agents |2 NLM | |
| 700 | 1 | |a Fernandez, Nicholas R |e verfasserin |4 aut | |
| 700 | 1 | |a Levine, Adrian |e verfasserin |4 aut | |
| 700 | 1 | |a Bianchi, Vanessa |e verfasserin |4 aut | |
| 700 | 1 | |a Stengs, Lucie K |e verfasserin |4 aut | |
| 700 | 1 | |a Chung, Jiil |e verfasserin |4 aut | |
| 700 | 1 | |a Negm, Logine |e verfasserin |4 aut | |
| 700 | 1 | |a Dimayacyac, Jose Rafael |e verfasserin |4 aut | |
| 700 | 1 | |a Chang, Yuan |e verfasserin |4 aut | |
| 700 | 1 | |a Nobre, Liana |e verfasserin |4 aut | |
| 700 | 1 | |a Ercan, Ayse B |e verfasserin |4 aut | |
| 700 | 1 | |a Sanchez-Ramirez, Santiago |e verfasserin |4 aut | |
| 700 | 1 | |a Sudhaman, Sumedha |e verfasserin |4 aut | |
| 700 | 1 | |a Edwards, Melissa |e verfasserin |4 aut | |
| 700 | 1 | |a Larouche, Valerie |e verfasserin |4 aut | |
| 700 | 1 | |a Samuel, David |e verfasserin |4 aut | |
| 700 | 1 | |a Van Damme, An |e verfasserin |4 aut | |
| 700 | 1 | |a Gass, David |e verfasserin |4 aut | |
| 700 | 1 | |a Ziegler, David S |e verfasserin |4 aut | |
| 700 | 1 | |a Bielack, Stefan S |e verfasserin |4 aut | |
| 700 | 1 | |a Koschmann, Carl |e verfasserin |4 aut | |
| 700 | 1 | |a Zelcer, Shayna |e verfasserin |4 aut | |
| 700 | 1 | |a Yalon-Oren, Michal |e verfasserin |4 aut | |
| 700 | 1 | |a Campino, Gadi Abede |e verfasserin |4 aut | |
| 700 | 1 | |a Sarosiek, Tomasz |e verfasserin |4 aut | |
| 700 | 1 | |a Nichols, Kim E |e verfasserin |4 aut | |
| 700 | 1 | |a Loret De Mola, Rebecca |e verfasserin |4 aut | |
| 700 | 1 | |a Bielamowicz, Kevin |e verfasserin |4 aut | |
| 700 | 1 | |a Sabel, Magnus |e verfasserin |4 aut | |
| 700 | 1 | |a Frojd, Charlotta A |e verfasserin |4 aut | |
| 700 | 1 | |a Wood, Matthew D |e verfasserin |4 aut | |
| 700 | 1 | |a Glover, Jason M |e verfasserin |4 aut | |
| 700 | 1 | |a Lee, Yi-Yen |e verfasserin |4 aut | |
| 700 | 1 | |a Vanan, Magimairajan |e verfasserin |4 aut | |
| 700 | 1 | |a Adamski, Jenny K |e verfasserin |4 aut | |
| 700 | 1 | |a Perreault, Sebastien |e verfasserin |4 aut | |
| 700 | 1 | |a Chamdine, Omar |e verfasserin |4 aut | |
| 700 | 1 | |a Hjort, Magnus Aasved |e verfasserin |4 aut | |
| 700 | 1 | |a Zapotocky, Michal |e verfasserin |4 aut | |
| 700 | 1 | |a Carceller, Fernando |e verfasserin |4 aut | |
| 700 | 1 | |a Wright, Erin |e verfasserin |4 aut | |
| 700 | 1 | |a Fedorakova, Ivana |e verfasserin |4 aut | |
| 700 | 1 | |a Lossos, Alexander |e verfasserin |4 aut | |
| 700 | 1 | |a Tanaka, Ryuma |e verfasserin |4 aut | |
| 700 | 1 | |a Osborn, Michael |e verfasserin |4 aut | |
| 700 | 1 | |a Blumenthal, Deborah T |e verfasserin |4 aut | |
| 700 | 1 | |a Aronson, Melyssa |e verfasserin |4 aut | |
| 700 | 1 | |a Bartels, Ute |e verfasserin |4 aut | |
| 700 | 1 | |a Huang, Annie |e verfasserin |4 aut | |
| 700 | 1 | |a Ramaswamy, Vijay |e verfasserin |4 aut | |
| 700 | 1 | |a Malkin, David |e verfasserin |4 aut | |
| 700 | 1 | |a Shlien, Adam |e verfasserin |4 aut | |
| 700 | 1 | |a Villani, Anita |e verfasserin |4 aut | |
| 700 | 1 | |a Dirks, Peter B |e verfasserin |4 aut | |
| 700 | 1 | |a Pugh, Trevor J |e verfasserin |4 aut | |
| 700 | 1 | |a Getz, Gad |e verfasserin |4 aut | |
| 700 | 1 | |a Maruvka, Yosef E |e verfasserin |4 aut | |
| 700 | 1 | |a Tsang, Derek S |e verfasserin |4 aut | |
| 700 | 1 | |a Ertl-Wagner, Birgit |e verfasserin |4 aut | |
| 700 | 1 | |a Hawkins, Cynthia |e verfasserin |4 aut | |
| 700 | 1 | |a Bouffet, Eric |e verfasserin |4 aut | |
| 700 | 1 | |a Morgenstern, Daniel A |e verfasserin |4 aut | |
| 700 | 1 | |a Tabori, Uri |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cancer discovery |d 2011 |g 14(2024), 2 vom: 08. Feb., Seite 258-273 |w (DE-627)NLM215937023 |x 2159-8290 |7 nnns |
| 773 | 1 | 8 | |g volume:14 |g year:2024 |g number:2 |g day:08 |g month:02 |g pages:258-273 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1158/2159-8290.CD-23-0559 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 14 |j 2024 |e 2 |b 08 |c 02 |h 258-273 | ||